Benzinga | Dec 13, 2021 04:30AM EST

Keybanc Maintains Overweight on Quest Diagnostics, Raises Price Target to $170

Keybanc maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $168 to $170.